Population Pharmacokinetics of Rivaroxaban in Chinese Patients with Non-Valvular Atrial Fibrillation: A Prospective Multicenter Study.
Feilong ZhangXuehai ChenTingting WuNianxu HuangLi LiDongdong YuanJing XiangNa WangWenjun ChenJin-Hua ZhangPublished in: Clinical pharmacokinetics (2022)
Our study was the first multicenter PPK model for rivaroxaban in Chinese patients with NVAF (Alfalfa-RIVAAF-PPK). The study found that 15 mg once daily may be suitable as the principal rivaroxaban dose for Chinese patients with NVAF. For patients with the rs4728709 mutation, it may be necessary to examine insufficient anticoagulation. We found that the rivaroxaban-calibrated chromogenic anti-Xa assay and HPLC-MS/MS method were highly linearly correlated. Prospective studies with larger sample sizes and real-world studies are needed for further verification.
Keyphrases
- atrial fibrillation
- venous thromboembolism
- ms ms
- oral anticoagulants
- left atrial
- catheter ablation
- direct oral anticoagulants
- pulmonary embolism
- left atrial appendage
- heart failure
- percutaneous coronary intervention
- clinical trial
- mass spectrometry
- high performance liquid chromatography
- liquid chromatography tandem mass spectrometry
- cross sectional
- case control
- aortic valve
- coronary artery disease
- monte carlo